TapewireFind a company

person · Reporting owner

DIEKMAN JOHN D

Disclosed activity across 10 companies

Tapewire entity
21275
SEC CIK
0001240357

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ARVINAS, INC.ARVN · Entity 535510% ownerSeptember 16, 2019September 18, 2019
Skye Bioscience, Inc.SKYE · Entity 809810% ownerSeptember 22, 2026September 24, 2026
Zai Lab LtdZLAB · Entity 4271DirectorJune 17, 2026June 22, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnotes3,098,567 Reported balance After 2019-09-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2019-09-16 · Other · Disposed 438,694 · Balance 3,098,567

F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by 5AM Ventures III, L.P. ("Ventures III") without consideration to its partners.

F2: These Securities are held of record by Ventures III.

F7: Partners III is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnotes79,856 Reported balance After 2019-09-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2019-09-16 · Other · Disposed 11,306 · Balance 79,856

F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by 5AM Co-Investors III, L.P. ("Co-Investors III") without consideration to its partners.

F4: These Securities are held of record by Co-Investors III.

F7: Partners III is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnotes85,396 Reported balance After 2019-09-16 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2019-09-16 · Other · Acquired 85,396 · Balance 85,396

F5: Represents a change in the form of ownership of 5AM Partners III, LLC ("Partners III") by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Ventures III and Co-Investors III.

F6: These Securities are held of record by Partners III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Partners III. Each of Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnotes17,079 Reported balance After 2019-09-16 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2019-09-16 · Other · Acquired 17,079 · Balance 17,079

F8: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to John D. Diekman and Susan P. Diekman Trustees Diekman Revocable Trust Dtd 6/30/95 ("Diekman Trust").

F9: These securities are held of record by Diekman Trust. Dr. Diekman is a trustee and beneficiary of the Diekman Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnotes17,079 Reported balance After 2019-09-16 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2019-09-16 · Other · Acquired 17,079 · Balance 17,079

F10: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to the Schwab Family Trust, Andrew J. Schwab and Catarina N. Schwab, as Trustees of the Schwab Family Trust, dated October 26, 2007 ("Schwab Family Trust").

F11: These securities are held of record by Schwab Family Trust. Mr. Schwab is a trustee and beneficiary of the Schwab Family Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnotes8,540 Reported balance After 2019-09-16 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 6 · 2019-09-16 · Other · Acquired 8,540 · Balance 8,540

F12: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to Scott M. Rocklage Revocable Trust dated 10/22/15; Trustees: Scott M. Rocklage and Patty B. Rocklage ("Rocklage Trust").

F13: These securities are held of record by Rocklage Trust. Dr. Rocklage is a trustee and beneficiary of the Rocklage Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnotes8,540 Reported balance After 2019-09-16 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 7 · 2019-09-16 · Other · Acquired 8,540 · Balance 8,540

F14: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to MADRock II LLC ("MADRock II").

F15: These securities are held of record by MADRock II. Dr. Rocklage is a manager of MADRock II and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnotes1,002 Reported balance After 2019-09-16 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 8 · 2019-09-16 · Other · Acquired 1,002 · Balance 1,002

F16: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Co-Investor III to Dr. John D. Diekman.

F17: These securities are held of record by Dr. John D. Diekman and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by 5AM Ventures III, L.P. ("Ventures III") without consideration to its partners.

F2: These Securities are held of record by Ventures III.

F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by 5AM Co-Investors III, L.P. ("Co-Investors III") without consideration to its partners.

F4: These Securities are held of record by Co-Investors III.

F5: Represents a change in the form of ownership of 5AM Partners III, LLC ("Partners III") by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Ventures III and Co-Investors III.

F6: These Securities are held of record by Partners III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Partners III. Each of Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of his pecuniary interest therein.

F7: Partners III is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

F8: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to John D. Diekman and Susan P. Diekman Trustees Diekman Revocable Trust Dtd 6/30/95 ("Diekman Trust").

F9: These securities are held of record by Diekman Trust. Dr. Diekman is a trustee and beneficiary of the Diekman Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

F10: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to the Schwab Family Trust, Andrew J. Schwab and Catarina N. Schwab, as Trustees of the Schwab Family Trust, dated October 26, 2007 ("Schwab Family Trust").

F11: These securities are held of record by Schwab Family Trust. Mr. Schwab is a trustee and beneficiary of the Schwab Family Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

F12: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to Scott M. Rocklage Revocable Trust dated 10/22/15; Trustees: Scott M. Rocklage and Patty B. Rocklage ("Rocklage Trust").

F13: These securities are held of record by Rocklage Trust. Dr. Rocklage is a trustee and beneficiary of the Rocklage Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

F14: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to MADRock II LLC ("MADRock II").

F15: These securities are held of record by MADRock II. Dr. Rocklage is a manager of MADRock II and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

F16: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Co-Investor III to Dr. John D. Diekman.

F17: These securities are held of record by Dr. John D. Diekman and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy 5AM Ventures II, L.P.0 Last balance in matching sequence After 2026-09-23 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2026-09-22 · Sale · Disposed 27,612 · Balance 114,851

F1: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Row 3 · 2026-09-23 · Sale · Disposed 114,851 · Balance 0

F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F1: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Common StockSEC Table I · non-derivativeIndirectBy 5AM Co-Investors II, L.P.0 Last balance in matching sequence After 2026-09-23 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 2 · 2026-09-22 · Sale · Disposed 1,088 · Balance 4,528

F2: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Row 4 · 2026-09-23 · Sale · Disposed 4,528 · Balance 0

F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F2: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Common StockSEC Table I · non-derivativeIndirectBy 5AM Ventures VII, L.P.981,269 Reported balance Holding disclosure · report date 2026-09-22 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 981,269

F4: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Filing footnotes · ownership attribution and instrument terms

F1: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

F2: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

F3: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $1.60 to $1.77 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

F4: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.

Zai Lab Ltd

Report date June 17, 2026 · Filed June 22, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
American Depositary SharesSEC Table I · non-derivativeDirect122,140 Reported balance After 2026-06-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-06-17 · Grant · Acquired 22,371 · Balance 122,140

F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.

F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.

F2: Represents restricted shares that vest in full on June 17, 2027, subject to the Reporting Person's continued service as a member of the issuer's board of directors through such vesting date.

Past disclosures · reporting ended (7)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Section 16 reporting ended · disclosed 2020-10-08. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnotes138,497 Reported balance After 2020-10-05 transaction · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · 2020-10-05 · Sale · Disposed 175,000 · Balance 138,497

F1: Shares are held directly by 5AM Opportunities I, L.P. ("Opportunities"), which is under common control with the 5AM IV Funds. The 5AM IV Funds and Opportunities expressly disclaim status as a "group" for purposes of this Form 4.

F2: 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities, except to the extent of its or his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnotes1,823,192 Reported balance Holding disclosure · report date 2020-10-05 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 1,823,192

F3: Shares are held directly by 5AM Ventures IV, L.P.

F4: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Dr. Scott M. Rocklage and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnotes75,965 Reported balance Holding disclosure · report date 2020-10-05 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 75,965

F5: Shares are held directly by 5AM Co-Investors IV, L.P.

F4: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Dr. Scott M. Rocklage and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Shares are held directly by 5AM Opportunities I, L.P. ("Opportunities"), which is under common control with the 5AM IV Funds. The 5AM IV Funds and Opportunities expressly disclaim status as a "group" for purposes of this Form 4.

F2: 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Dr. Parmar disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities, except to the extent of its or his pecuniary interest therein.

F3: Shares are held directly by 5AM Ventures IV, L.P.

F4: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Dr. Scott M. Rocklage and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F5: Shares are held directly by 5AM Co-Investors IV, L.P.

Audentes Therapeutics, Inc.

Report date April 24, 2017 · Filed April 26, 2017

Jointly reported with 5AM Partners III, LLC, 5AM Co-Investors III, L.P., 5AM VENTURES III, L.P., Schwab Andrew J., ROCKLAGE SCOTT M

Section 16 reporting ended · disclosed 2017-04-26. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy 5AM Co-Investors III, L.P.64,431 Reported balance After 2017-04-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2017-04-24 · Purchase · Acquired 4,331 · Balance 64,431

F1: 5AM Partners III, LLC is the general partner of 5AM Ventures III, L.P. and 5AM Co-Investors III, L.P. Dr. John Diekman, Andrew Schwab and Dr. Scott Rocklage are the managing members of 5AM Partners III. 5AM Partners III, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by 5AM Ventures III, L.P. and 5AM Co-Investors III, L.P. Dr. Diekman, Mr. Schwab and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM Ventures III, L.P. and 5AM Co-Investors III, L.P. Each of 5AM Partners III, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares, except to the extent of its pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy 5AM Ventures III, L.P.2,500,113 Reported balance After 2017-04-24 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2017-04-24 · Purchase · Acquired 168,082 · Balance 2,500,113

F1: 5AM Partners III, LLC is the general partner of 5AM Ventures III, L.P. and 5AM Co-Investors III, L.P. Dr. John Diekman, Andrew Schwab and Dr. Scott Rocklage are the managing members of 5AM Partners III. 5AM Partners III, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by 5AM Ventures III, L.P. and 5AM Co-Investors III, L.P. Dr. Diekman, Mr. Schwab and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM Ventures III, L.P. and 5AM Co-Investors III, L.P. Each of 5AM Partners III, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares, except to the extent of its pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: 5AM Partners III, LLC is the general partner of 5AM Ventures III, L.P. and 5AM Co-Investors III, L.P. Dr. John Diekman, Andrew Schwab and Dr. Scott Rocklage are the managing members of 5AM Partners III. 5AM Partners III, LLC may be deemed to have sole voting and investment power over the shares beneficially owned by 5AM Ventures III, L.P. and 5AM Co-Investors III, L.P. Dr. Diekman, Mr. Schwab and Dr. Rocklage may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM Ventures III, L.P. and 5AM Co-Investors III, L.P. Each of 5AM Partners III, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares, except to the extent of its pecuniary interest therein.

Crinetics Pharmaceuticals, Inc.

Report date June 21, 2019 · Filed June 25, 2019

Jointly reported with 5AM Ventures IV, L.P., 5AM Co-Investors IV, L.P., 5AM Partners IV, LLC, ROCKLAGE SCOTT M, Schwab Andrew J.

Section 16 reporting ended · disclosed 2019-06-25. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footote2,267,797 Reported balance After 2019-06-21 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2019-06-21 · Sale · Disposed 240,000 · Balance 2,267,797

F1: These securities are held by by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footote94,489 Reported balance After 2019-06-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2019-06-21 · Sale · Disposed 10,000 · Balance 94,489

F2: These securities are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Co-Investors IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are held by by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

F2: These securities are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Co-Investors IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Section 16 reporting ended · disclosed 2020-11-14. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote2,187,428 Reported balance After 2020-11-11 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2020-11-11 · Sale · Disposed 657,117 · Balance 2,187,428

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote91,142 Reported balance After 2020-11-11 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2020-11-11 · Sale · Disposed 27,379 · Balance 91,142

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV" and, collectively with Ventures IV, the "5AM IV Funds"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote384,496 Reported balance After 2020-11-11 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2020-11-11 · Sale · Disposed 115,504 · Balance 384,496

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The shares are held by 5AM Opportunities I, L.P. ("Opportunities I"), which is under common control with the 5AM IV Funds. The 5AM IV Funds and Opportunities I expressly disclaim status as a "group" for purposes of this Form 4. 5AM Opportunities I (GP), LLC ("Opportunities I GP") is the sole general partner of Opportunities I. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities I GP, and have shared voting and investment power over the shares beneficially owned by Opportunities I. Each of Opportunities I GP and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

F3: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV" and, collectively with Ventures IV, the "5AM IV Funds"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

F4: The shares are held by 5AM Opportunities I, L.P. ("Opportunities I"), which is under common control with the 5AM IV Funds. The 5AM IV Funds and Opportunities I expressly disclaim status as a "group" for purposes of this Form 4. 5AM Opportunities I (GP), LLC ("Opportunities I GP") is the sole general partner of Opportunities I. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Opportunities I GP, and have shared voting and investment power over the shares beneficially owned by Opportunities I. Each of Opportunities I GP and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Section 16 reporting ended · disclosed 2023-04-12. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Common StockSEC Table I · non-derivativeIndirectBy 5AM Ventures IV, L.P.0 Reported balance After 2023-04-10 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2023-04-10 · Sale · Disposed 12,836,489 · Balance 0

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The shares are directly held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Class A Common StockSEC Table I · non-derivativeIndirectBy 5AM Co-Investors IV, L.P.0 Reported balance After 2023-04-10 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2023-04-10 · Sale · Disposed 534,855 · Balance 0

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The shares are directly held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

Class A Common StockSEC Table I · non-derivativeIndirectBy 5AM Opportunities I, L.P.200,000 Reported balance After 2023-04-10 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2023-04-10 · Sale · Disposed 3,172,769 · Balance 200,000

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.11 to $0.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: The shares are directly held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

F3: The shares are directly held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Dr. Rocklage and Mr. Schwab disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein.

F4: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein.

Section 16 reporting ended · disclosed 2020-12-29. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnote4,354,484 Reported balance After 2020-12-22 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2020-12-22 · Sale · Disposed 480,000 · Balance 4,354,484

F1: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectSee footnote181,435 Reported balance After 2020-12-22 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2020-12-22 · Sale · Disposed 20,000 · Balance 181,435

F2: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

F2: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Section 16 reporting ended · disclosed 2022-10-11. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy 5AM Ventures IV, L.P.2,231,601 Last balance in matching sequence After 2022-10-10 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2022-10-06 · Sale · Disposed 30,457 · Balance 2,688,014

F1: The shares are directly held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Row 4 · 2022-10-10 · Sale · Disposed 456,413 · Balance 2,231,601

F1: The shares are directly held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy 5AM Co-Investors IV, L.P.92,983 Last balance in matching sequence After 2022-10-10 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 2 · 2022-10-06 · Sale · Disposed 1,269 · Balance 112,000

F2: The shares are directly held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Row 5 · 2022-10-10 · Sale · Disposed 19,017 · Balance 92,983

F2: The shares are directly held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Common StockSEC Table I · non-derivativeIndirectBy 5AM Opportunities I, L.P.410,268 Last balance in matching sequence After 2022-10-10 transaction · row 6 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 3 · 2022-10-06 · Sale · Disposed 5,808 · Balance 497,304

F3: Shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his pecuniary interest therein.

Row 6 · 2022-10-10 · Sale · Disposed 87,036 · Balance 410,268

F3: Shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are directly held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

F2: The shares are directly held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

F3: Shares are directly held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab is a managing member of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of such shares, except to the extent of its or his pecuniary interest therein.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
June 16, 2020 Filed Jun 18, 2020 23:22 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 SaleCommon Stock 115,357 $33.30 $3,841,388.10
Disclosure

SEC source: 0001209191-20-037714 · doc4.xml · nonDerivative · entry 1

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,823,192

F1 · ownership.direct: Shares are held directly by 5AM Ventures IV, L.P.

F2 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F1 · ownership.nature: Shares are held directly by 5AM Ventures IV, L.P.

F2 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Read SEC document
June 11, 2020 Filed Jun 16, 2020 01:12 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 SaleCommon Stock 9,800 $28.75 $281,776.46
Disclosure

SEC source: 0001209191-20-036845 · doc4.xml · nonDerivative · entry 2

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 80,772

F2 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F3 · ownership.direct: Shares are held directly by 5AM Co-Investors IV, L.P.

F2 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F3 · ownership.nature: Shares are held directly by 5AM Co-Investors IV, L.P.

Read SEC document
June 11, 2020 Filed Jun 16, 2020 01:12 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 SaleCommon Stock 235,200 $28.75 $6,762,635.04
Disclosure

SEC source: 0001209191-20-036845 · doc4.xml · nonDerivative · entry 1

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,938,549

F1 · ownership.direct: Shares are held directly by 5AM Ventures IV, L.P.

F2 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F1 · ownership.nature: Shares are held directly by 5AM Ventures IV, L.P.

F2 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Read SEC document
May 19, 2020 Filed May 22, 2020 01:31 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 SaleCommon Stock 10,200 $35.15 $358,530.00
Disclosure

SEC source: 0001209191-20-031545 · doc4.xml · nonDerivative · entry 2

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 90,572

F2 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F3 · ownership.direct: Shares are held directly by 5AM Co-Investors IV, L.P.

F2 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F3 · ownership.nature: Shares are held directly by 5AM Co-Investors IV, L.P.

Read SEC document
May 19, 2020 Filed May 22, 2020 01:31 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 SaleCommon Stock 244,800 $35.15 $8,604,720.00
Disclosure

SEC source: 0001209191-20-031545 · doc4.xml · nonDerivative · entry 1

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,173,748

F1 · ownership.direct: Shares are held directly by 5AM Ventures IV, L.P.

F2 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F1 · ownership.nature: Shares are held directly by 5AM Ventures IV, L.P.

F2 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Read SEC document
October 07, 2019 Filed Oct 9, 2019 22:23 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 ConversionSeries C Convertible Preferred Stock · Derivative 20,519 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-19-053617 · a4.xml · derivative · entry 9

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 20,519 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F3 · ownership.direct: Shares are held directly by 5AM Co-Investors IV, L.P.

F4 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F3 · ownership.nature: Shares are held directly by 5AM Co-Investors IV, L.P.

F4 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Read SEC document
October 07, 2019 Filed Oct 9, 2019 22:23 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 ConversionSeries C Convertible Preferred Stock · Derivative 492,475 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-19-053617 · a4.xml · derivative · entry 8

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 492,475 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: Shares are held directly by 5AM Ventures IV, L.P.

F4 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F2 · ownership.nature: Shares are held directly by 5AM Ventures IV, L.P.

F4 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Read SEC document
October 07, 2019 Filed Oct 9, 2019 22:23 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 ConversionSeries B Convertible Preferred Stock · Derivative 79,746 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-19-053617 · a4.xml · derivative · entry 7

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 79,746 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F3 · ownership.direct: Shares are held directly by 5AM Co-Investors IV, L.P.

F4 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F3 · ownership.nature: Shares are held directly by 5AM Co-Investors IV, L.P.

F4 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Read SEC document
October 07, 2019 Filed Oct 9, 2019 22:23 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 ConversionSeries B Convertible Preferred Stock · Derivative 1,913,910 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-19-053617 · a4.xml · derivative · entry 6

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 1,913,910 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: Shares are held directly by 5AM Ventures IV, L.P.

F4 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F2 · ownership.nature: Shares are held directly by 5AM Ventures IV, L.P.

F4 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Read SEC document
October 07, 2019 Filed Oct 9, 2019 22:23 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 PurchaseCommon Stock 333,333 $15.00 $4,999,995.00
Disclosure

SEC source: 0001104659-19-053617 · a4.xml · nonDerivative · entry 5

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 333,333

F5 · ownership.direct: Shares are held directly by 5AM Opportunities I, L.P. ("Opportunities"), which is under common control with the 5AM IV Funds. The 5AM IV Funds and Opportunities expressly disclaim status as a "group" for purposes of this Form 4.

F6 · ownership.direct: 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Mr. Parmar disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities, except to the extent of its or his pecuniary interest therein.

F5 · ownership.nature: Shares are held directly by 5AM Opportunities I, L.P. ("Opportunities"), which is under common control with the 5AM IV Funds. The 5AM IV Funds and Opportunities expressly disclaim status as a "group" for purposes of this Form 4.

F6 · ownership.nature: 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP, Mr. Schwab and Mr. Parmar disclaims beneficial ownership of the shares of Common Stock held directly by Opportunities, except to the extent of its or his pecuniary interest therein.

Read SEC document
October 07, 2019 Filed Oct 9, 2019 22:23 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 ConversionCommon Stock 20,519 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-19-053617 · a4.xml · nonDerivative · entry 4

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 100,772

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F3 · ownership.direct: Shares are held directly by 5AM Co-Investors IV, L.P.

F4 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F3 · ownership.nature: Shares are held directly by 5AM Co-Investors IV, L.P.

F4 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Read SEC document
October 07, 2019 Filed Oct 9, 2019 22:23 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 ConversionCommon Stock 492,475 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-19-053617 · a4.xml · nonDerivative · entry 3

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,418,548

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: Shares are held directly by 5AM Ventures IV, L.P.

F4 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F2 · ownership.nature: Shares are held directly by 5AM Ventures IV, L.P.

F4 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Read SEC document
October 07, 2019 Filed Oct 9, 2019 22:23 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 ConversionCommon Stock 79,746 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-19-053617 · a4.xml · nonDerivative · entry 2

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 80,253

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F3 · ownership.direct: Shares are held directly by 5AM Co-Investors IV, L.P.

F4 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F3 · ownership.nature: Shares are held directly by 5AM Co-Investors IV, L.P.

F4 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Read SEC document
October 07, 2019 Filed Oct 9, 2019 22:23 UTC Aprea Therapeutics, Inc. APRE · Entity 7948 ConversionCommon Stock 1,913,910 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-19-053617 · a4.xml · nonDerivative · entry 1

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

5AM Opportunities I, L.P. · CIK 0001753000 · 10% owner

5AM Opportunities I (GP), LLC · CIK 0001790778 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

PARMAR KUSH · CIK 0001664281 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,926,073

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's Common Stock ("Common Stock"), on a 1-for-1 basis, immediately prior to the completion of the Issuer's initial public offering for no additional consideration. The Preferred Stock had no expiration date.

F2 · ownership.direct: Shares are held directly by 5AM Ventures IV, L.P.

F4 · ownership.direct: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

F2 · ownership.nature: Shares are held directly by 5AM Ventures IV, L.P.

F4 · ownership.nature: 5AM Partners IV, LLC is the sole general partner of each of 5AM Ventures IV, L.P. and 5AM Co-Investors IV, L.P. (collectively, the "5AM IV Funds"). Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners IV, LLC and may be deemed to have shared voting and investment power over the shares beneficially owned by the 5AM IV Funds. Each of 5AM Partners IV, LLC, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock and Preferred Stock held directly by the 5AM IV Funds, except to the extent of its or his pecuniary interest therein.

Read SEC document
September 24, 2019 Filed Dec 20, 2019 00:08 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 GrantStock Option (right to buy) · Derivative 11,000 $0.00 Strike: $9.15 $0.00
Disclosure

SEC source: 0001567619-19-023457 · doc1.xml · derivative · entry 1

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,000

Underlying: Common Stock · 11,000 shares

Expires 2029-09-23

F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 21:32 UTC ARVINAS, INC. ARVN · Entity 5355 OtherCommon Stock 1,002 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 8

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,002

F16 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Co-Investor III to Dr. John D. Diekman.

F17 · ownership.nature: These securities are held of record by Dr. John D. Diekman and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 21:32 UTC ARVINAS, INC. ARVN · Entity 5355 OtherCommon Stock 8,540 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 7

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 8,540

F14 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to MADRock II LLC ("MADRock II").

F15 · ownership.nature: These securities are held of record by MADRock II. Dr. Rocklage is a manager of MADRock II and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 21:32 UTC ARVINAS, INC. ARVN · Entity 5355 OtherCommon Stock 8,540 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 6

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 8,540

F12 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to Scott M. Rocklage Revocable Trust dated 10/22/15; Trustees: Scott M. Rocklage and Patty B. Rocklage ("Rocklage Trust").

F13 · ownership.nature: These securities are held of record by Rocklage Trust. Dr. Rocklage is a trustee and beneficiary of the Rocklage Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 21:32 UTC ARVINAS, INC. ARVN · Entity 5355 OtherCommon Stock 17,079 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 5

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 17,079

F10 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to the Schwab Family Trust, Andrew J. Schwab and Catarina N. Schwab, as Trustees of the Schwab Family Trust, dated October 26, 2007 ("Schwab Family Trust").

F11 · ownership.nature: These securities are held of record by Schwab Family Trust. Mr. Schwab is a trustee and beneficiary of the Schwab Family Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 21:32 UTC ARVINAS, INC. ARVN · Entity 5355 OtherCommon Stock 17,079 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 4

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 17,079

F8 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to John D. Diekman and Susan P. Diekman Trustees Diekman Revocable Trust Dtd 6/30/95 ("Diekman Trust").

F9 · ownership.nature: These securities are held of record by Diekman Trust. Dr. Diekman is a trustee and beneficiary of the Diekman Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 21:32 UTC ARVINAS, INC. ARVN · Entity 5355 OtherCommon Stock 85,396 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 3

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 85,396

F5 · kind: Represents a change in the form of ownership of 5AM Partners III, LLC ("Partners III") by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Ventures III and Co-Investors III.

F6 · ownership.nature: These Securities are held of record by Partners III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Partners III. Each of Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 21:32 UTC ARVINAS, INC. ARVN · Entity 5355 OtherCommon Stock 11,306 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 2

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 79,856

F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by 5AM Co-Investors III, L.P. ("Co-Investors III") without consideration to its partners.

F4 · ownership.nature: These Securities are held of record by Co-Investors III.

F7 · ownership.nature: Partners III is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
September 16, 2019 Filed Sep 18, 2019 21:32 UTC ARVINAS, INC. ARVN · Entity 5355 OtherCommon Stock 438,694 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 1

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 3,098,567

F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by 5AM Ventures III, L.P. ("Ventures III") without consideration to its partners.

F2 · ownership.nature: These Securities are held of record by Ventures III.

F7 · ownership.nature: Partners III is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
June 28, 2019 Filed Jul 1, 2019 20:01 UTC ARVINAS, INC. ARVN · Entity 5355 SaleCommon Stock 9,045 $22.02 $199,170.90
Disclosure

SEC source: 0001104659-19-038785 · a4.xml · nonDerivative · entry 4

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 91,162

F2 · ownership.nature: These Securities are held of record by 5AM Co-Investors III, L.P. ("Co-Investors III").

F3 · ownership.nature: 5AM Partners III, LLC ("Partners III") is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
June 28, 2019 Filed Jul 1, 2019 20:01 UTC ARVINAS, INC. ARVN · Entity 5355 SaleCommon Stock 350,955 $22.02 $7,728,029.10
Disclosure

SEC source: 0001104659-19-038785 · a4.xml · nonDerivative · entry 3

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,537,261

F1 · ownership.nature: These Securities are held of record by 5AM Ventures III, L.P. ("Ventures III").

F3 · ownership.nature: 5AM Partners III, LLC ("Partners III") is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
June 27, 2019 Filed Jul 1, 2019 20:01 UTC ARVINAS, INC. ARVN · Entity 5355 SaleCommon Stock 11,306 $21.75 $245,905.50
Disclosure

SEC source: 0001104659-19-038785 · a4.xml · nonDerivative · entry 2

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 100,207

F2 · ownership.nature: These Securities are held of record by 5AM Co-Investors III, L.P. ("Co-Investors III").

F3 · ownership.nature: 5AM Partners III, LLC ("Partners III") is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
June 27, 2019 Filed Jul 1, 2019 20:01 UTC ARVINAS, INC. ARVN · Entity 5355 SaleCommon Stock 438,694 $21.75 $9,541,594.50
Disclosure

SEC source: 0001104659-19-038785 · a4.xml · nonDerivative · entry 1

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 3,888,216

F1 · ownership.nature: These Securities are held of record by 5AM Ventures III, L.P. ("Ventures III").

F3 · ownership.nature: 5AM Partners III, LLC ("Partners III") is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
June 21, 2019 Filed Jun 25, 2019 23:03 UTC Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 SaleCommon Stock 10,000 $22.20 $222,000.00
Disclosure

SEC source: 0001104659-19-037468 · a4.xml · nonDerivative · entry 2

5AM Ventures IV, L.P. · CIK 0001589315 · Former 10% holder

5AM Co-Investors IV, L.P. · CIK 0001593361 · Former 10% holder

5AM Partners IV, LLC · CIK 0001589314 · Former 10% holder

ROCKLAGE SCOTT M · CIK 0001219014 · Former 10% holder

DIEKMAN JOHN D · CIK 0001240357 · Former 10% holder

Schwab Andrew J. · CIK 0001598549 · Former 10% holder

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footote

Disclosed balance after: 94,489

F2 · ownership.nature: These securities are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Co-Investors IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Read SEC document
June 21, 2019 Filed Jun 25, 2019 23:03 UTC Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 SaleCommon Stock 240,000 $22.20 $5,328,000.00
Disclosure

SEC source: 0001104659-19-037468 · a4.xml · nonDerivative · entry 1

5AM Ventures IV, L.P. · CIK 0001589315 · Former 10% holder

5AM Co-Investors IV, L.P. · CIK 0001593361 · Former 10% holder

5AM Partners IV, LLC · CIK 0001589314 · Former 10% holder

ROCKLAGE SCOTT M · CIK 0001219014 · Former 10% holder

DIEKMAN JOHN D · CIK 0001240357 · Former 10% holder

Schwab Andrew J. · CIK 0001598549 · Former 10% holder

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footote

Disclosed balance after: 2,267,797

F1 · ownership.nature: These securities are held by by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Read SEC document
June 07, 2019 Filed Jun 11, 2019 09:58 UTC ARVINAS, INC. ARVN · Entity 5355 SaleCommon Stock 4,774 $19.65 $93,809.10
Disclosure

SEC source: 0001104659-19-034661 · a4.xml · nonDerivative · entry 2

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 111,513

F2 · ownership.nature: These Securities are held of record by 5AM Co-Investors III, L.P. ("Co-Investors III").

F3 · ownership.nature: 5AM Partners III, LLC ("Partners III") is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
June 07, 2019 Filed Jun 11, 2019 09:58 UTC ARVINAS, INC. ARVN · Entity 5355 SaleCommon Stock 185,226 $19.65 $3,639,690.90
Disclosure

SEC source: 0001104659-19-034661 · a4.xml · nonDerivative · entry 1

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 4,326,910

F1 · ownership.nature: These Securities are held of record by 5AM Ventures III, L.P. ("Ventures III").

F3 · ownership.nature: 5AM Partners III, LLC ("Partners III") is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 29, 2019 01:14 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionSeries B Preferred Stock · Derivative 24,101 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012282 · doc1.xml · derivative · entry 10

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 24,101 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · derivative.exercise_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · derivative.underlying_shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 29, 2019 01:14 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionSeries A Preferred Stock · Derivative 71,745 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012282 · doc1.xml · derivative · entry 9

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 71,745 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · derivative.exercise_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · derivative.expiration_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · derivative.underlying_shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 29, 2019 01:14 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionSeries B Preferred Stock · Derivative 578,447 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012282 · doc1.xml · derivative · entry 8

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 578,447 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · derivative.exercise_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · derivative.expiration_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · derivative.underlying_shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 29, 2019 01:14 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionSeries A Preferred Stock · Derivative 1,721,898 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012282 · doc1.xml · derivative · entry 7

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 1,721,898 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · derivative.exercise_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · derivative.expiration_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · derivative.underlying_shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 29, 2019 01:14 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 PurchaseCommon Stock 10,000 $10.00 $100,000.00
Disclosure

SEC source: 0001567619-19-012282 · doc1.xml · nonDerivative · entry 6

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 118,521

F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 29, 2019 01:14 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 PurchaseCommon Stock 240,000 $10.00 $2,400,000.00
Disclosure

SEC source: 0001567619-19-012282 · doc1.xml · nonDerivative · entry 5

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,844,545

F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 29, 2019 01:14 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionCommon Stock 24,101 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012282 · doc1.xml · nonDerivative · entry 4

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 108,521

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 29, 2019 01:14 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionCommon Stock 71,745 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012282 · doc1.xml · nonDerivative · entry 3

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 84,420

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 29, 2019 01:14 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionCommon Stock 578,447 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012282 · doc1.xml · nonDerivative · entry 2

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,604,545

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F4 · shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 28, 2019 Filed May 29, 2019 01:14 UTC IDEAYA Biosciences, Inc. IDYA · Entity 4069 ConversionCommon Stock 1,721,898 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-19-012282 · doc1.xml · nonDerivative · entry 1

DIEKMAN JOHN D · CIK 0001240357 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,026,098

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F2 · shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering.

F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Dr. Diekman disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Read SEC document
May 16, 2019 Filed May 20, 2019 20:26 UTC Q32 Bio Inc. FIXX · Entity 5594 SaleCommon Stock 24,600 $21.47 $528,162.00
Disclosure

SEC source: 0001104659-19-030566 · a4.xml · nonDerivative · entry 2

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 221,435

F2 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Read SEC document
May 16, 2019 Filed May 20, 2019 20:26 UTC Q32 Bio Inc. FIXX · Entity 5594 SaleCommon Stock 590,400 $21.47 $12,675,888.00
Disclosure

SEC source: 0001104659-19-030566 · a4.xml · nonDerivative · entry 1

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 5,314,484

F1 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Read SEC document
March 28, 2019 Filed Apr 1, 2019 17:31 UTC ARVINAS, INC. ARVN · Entity 5355 SaleCommon Stock 9,073 $14.16 $128,451.00
Disclosure

SEC source: 0001104659-19-019024 · a4.xml · nonDerivative · entry 2

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 116,287

F2 · ownership.nature: These Securities are held of record by 5AM Co-Investors III, L.P. ("Co-Investors III").

F3 · ownership.nature: 5AM Partners III, LLC ("Partners III") is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
March 28, 2019 Filed Apr 1, 2019 17:31 UTC ARVINAS, INC. ARVN · Entity 5355 SaleCommon Stock 352,056 $14.16 $4,984,232.82
Disclosure

SEC source: 0001104659-19-019024 · a4.xml · nonDerivative · entry 1

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnotes

Disclosed balance after: 4,512,136

F1 · ownership.nature: These Securities are held of record by 5AM Ventures III, L.P. ("Ventures III").

F3 · ownership.nature: 5AM Partners III, LLC ("Partners III") is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

Read SEC document
March 18, 2019 Filed Mar 20, 2019 20:48 UTC Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 SaleCommon Stock 6,194 $24.25 $150,208.84
Disclosure

SEC source: 0001104659-19-016338 · a4.xml · nonDerivative · entry 2

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 104,489

F2 · ownership.nature: These securities are held by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Partners IV is the sole general partner of Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Co-Investors IV, and have shared voting and investment power over the shares beneficially owned by Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Read SEC document
March 18, 2019 Filed Mar 20, 2019 20:48 UTC Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 SaleCommon Stock 148,645 $24.25 $3,604,745.30
Disclosure

SEC source: 0001104659-19-016338 · a4.xml · nonDerivative · entry 1

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,507,797

F1 · ownership.nature: These securities are held by by 5AM Ventures IV, L.P. ("Ventures IV"). 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

Read SEC document
February 20, 2019 Filed Feb 23, 2019 01:06 UTC Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 OtherCommon Stock 783 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-010154 · a4.xml · nonDerivative · entry 11

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,723

F19 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Co-Investors IV to the Scott M. Rocklage Trust u/d/t/ dated October 22, 2015; Trustees: Scott M. Rocklage and Patty B. Rocklage ("Rocklage Trust II").

F20 · ownership.nature: These securities are held of record by the Rocklage Trust II. Dr. Rocklage is a trustee and beneficiary of the Rocklage Trust II and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document
February 20, 2019 Filed Feb 23, 2019 01:06 UTC Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 OtherCommon Stock 783 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-010154 · a4.xml · nonDerivative · entry 10

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,723

F18 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Co-Investors IV to the Diekman Trust.

F12 · ownership.nature: These securities are held of record by Diekman Trust. Dr. Diekman is a trustee and beneficiary of the Diekman Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document
February 20, 2019 Filed Feb 23, 2019 01:06 UTC Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 OtherCommon Stock 783 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-010154 · a4.xml · nonDerivative · entry 9

5AM Ventures IV, L.P. · CIK 0001589315 · 10% owner

5AM Co-Investors IV, L.P. · CIK 0001593361 · 10% owner

5AM Partners IV, LLC · CIK 0001589314 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,723

F17 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Co-Investors IV to the Schwab Family Trust.

F10 · ownership.nature: These securities are held of record by Schwab Family Trust. Mr. Schwab is a trustee and beneficiary of the Schwab Family Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.